DCVC Bio retweeted
A look at what @DCVC /@DCVCBio founders delivered /this week/: 💪 🚚
🤖 Fleet-scale humanoid deployment: @agilityrobotics expanded its commercial footprint with GXO Logistics, soon moving into facilities across North Carolina and Tennessee after crossing an unprecedented 100,000-tote operational milestone.
⚛️ Microreactor regulatory progress: @RadiantNuclear cleared a major hurdle as the US Dep't of @ENERGY approved the documented safety analysis for its Kaleidos test unit at @INL, moving it one step closer to criticality.
🧬 Predictive computational biology: Latus Bio published the first predictive computational model of Huntington’s disease built on human data in Nature Communications, along with preclinical data supporting its gene therapy candidate LTS-201 as a potentially disease-modifying treatment. This is BIG.
🔬 Rapid stem cell reprogramming: @SyntaxBio drew major biotech coverage for using its CRISPR-based Cellgorithm platform to differentiate human stem cells into pancreatic beta cells in just four days, an early step toward faster development of cell therapies for Type 1 diabetes.
🎯 Clinical precision oncology: @FrontierMeds posted a standout 56% confirmed response rate in its Phase 1 lung cancer trial (FMC-376) presented at the ESMO - European Society for Medical Oncology Congress.
💡 Quantum photonics breakthrough: @NVisionQuantum published research introducing the first organic molecule capable of directly linking quantum processors with light, unlocking a scalable path for optical quantum networking.
🧠 Frontier AI compute architecture: Unconventional AI (@unconvAI) AI CEO @NaveenGRao joined @20vcFund to talk about why inference could be a $10 trillion market and why robotics could be 100x bigger than coding agents.
Onward!
DCVC Bio retweeted
𝐂𝐨𝐧𝐯𝐞𝐫𝐠𝐞𝐧𝐜𝐞 𝐅𝐨𝐫𝐮𝐦: Chicago based Grove Biopharma has engineered a technology, Bionic Biologics, that it hopes will give its therapies the versatility of biologics in a small molecule format. #ConvergenceForum
DCVC Bio retweeted
Gene therapy is moving from promise to precision.
Latus Bio added a $43M Series A extension from @8vc, @DCVCBio, and Hatch BioFund, bringing the round to $97M. P. Peter Ghoroghchian is building an AI-enabled platform focused on precision AAV delivery for neurological disease.
The next biotech edge will come from pairing better vectors with better computational judgment.
DCVC Bio retweeted
Orca-T, our investigational allogeneic T-cell immunotherapy, is a finalist in the Biotech Innovation category of the Fierce Innovation Awards: Life Sciences Edition 2025!
This award recognizes the companies and innovations pushing science forward to transform the field of life sciences. We're proud of the work we do on behalf of patients, and honored to be included.
To learn more: orcabio.com/
#FierceLifeSciencesAwards and #FierceInnovationAwards
DCVC Bio retweeted
Today, Orca Bio announced the FDA Acceptance and Priority Review of the Biologics License Application (BLA) for Orca-T to treat hematological malignancies.
Read more in the press release: bit.ly/4q1Uzkw
#celltherapy #hematology #oncology
DCVC Bio retweeted
Augmented RNA reality is emerging! @creyonbio has the ability to programmatically engineer knowably safe and effective siRNAs, ASOs, and other oligo therapies to unlock a huge range of therapeutic advances👇
dcvc.com/news-insights/creyo…
DCVC Bio retweeted
Creyon Bio names Serge Messerlian as CEO and appoints Kiersten Stead, PhD, to the Board. With revitalized leadership & AI-powered oligo tech, we're advancing therapies in CNS, neuromuscular, & immunologic diseases. creyonbio.com/latest-news/
#BiotechNews #AIinHealthcare
DCVC Bio retweeted
We're thrilled to announce that thanks to the most forward-looking investors on the planet, we’ve raised over $700 million for a healthier planet and healthier lives, bringing our total funding closed over the last 2.5 years to over $1.6 billion 🌎🧬🌾
bit.ly/4eHLNl9
DCVC Bio retweeted
Our second annual Deep Tech Opportunities Report is here, offering an extended look at deep tech and how we believe it can help build a future of abundance and resilience.
We hope you enjoy it — and the possibilities it signals.
dcvc.com/news-insights/dcvc-…
DCVC Bio retweeted
Please welcome Serge Messerlian @DCVC, to our Board of Directors!
With extensive leadership in life sciences, Serge brings valuable expertise to support our mission of reimagining drug development through AI-enabled engineering of OBMs.
brnw.ch/21wMua9
DCVC Bio retweeted
"Digital twins are the future of medicine. They basically replace our entire medical system; you basically turn medicine into a predictive science, you run experiments, and you optimize patients' treatments" — @charleskfisher in the @ZDNET article, "How digital twins could save time, money, and lives in developing prescription drugs" by @TiernanRayTech 🚀 zdnet.com/article/how-digita…
DCVC Bio retweeted
"The days of promising technology are behind us - be a builder."
hubs.la/Q02LYsHZ0
DCVC Bio retweeted
🌐 According to the @WHO, major depressive disorder impacts approximately 280 million people globally, while schizophrenia affects about 24 million. To accelerate #clinicaldevelopment and bring new treatments to patients faster, we launched #digitaltwin generators for both #schizophrenia and #majordepressivedisorder last month. Explore them here: unlearn.ai/digital-twin-gene…
DCVC Bio retweeted
Our CEO @chrihart proposes a paradigm shift in how we approach oligonucleotide-based medicine development, emphasizing the need to understand the complex interplay between sequence and chemistry.
Read more in @NAInsights: insights.bio/nucleic-acid-in…
DCVC Bio retweeted
Vogue Italia spotlights our co-founder Sophia Wang, and her unique perspective as an artist and writer whose creative practice guides her work as a biotech entrepreneur. See the full feature: vogue.it/article/mycoworks-c…
DCVC Bio retweeted
Today, Cadillac introduces the SOLLEI concept vehicle, the ultimate design expression of a coach-built luxury electric convertible. SOLLEI is Cadillac’s first concept vehicle to incorporate an innovative bio-based material developed in collaboration with MycoWorks.
DCVC Bio retweeted
“[Unlearn is] typically working on running clinical trials where we might be able to reduce the number of patients who get the placebo by somewhere like – 50%.”
Thanks to @heatherdcouture for featuring our founder and CEO, @charleskfisher on the #ImpactAI podcast 🚀 Listen now: bit.ly/3RaPera
DCVC Bio retweeted
Join us at #ASGCT2024 where our CMO, David Dimmock, MD, will present clinical data showing how we used our AI-enabled platform to engineer an antisense oligonucleotide investigational therapy for treatment of an ultra-rare disease. @ASGCTherapy
DCVC Bio retweeted
Today at #ASGCT24: @jaffeab, SVP, Head of Research, shared new data on our #EpigeneticEditors showing they efficiently, specifically, and durably target #HBV + #PCSK9 and are reversible in vivo.
#ASGCT2024
